【Animal Modeling】-FTS and NIRF conjugated compound for imaging and treatment of mouse tumor models

  Objective: To study the tumor-targeting properties of farnesyl thiosalicylic acid (FTS) and heptamethylamine carbocyanine (Near-infrared, NIR) fluorescent dye binding compound and its application in in vivo imaging, in order to clarify its effect Inhibition of tumor growth.

  Method: Culture human breast cancer cells MCF-7, glioma cells U251 and prostate cancer cells PC3 in the logarithmic growth phase, and then add different concentrations of FTS and FTS-IR783 to these two compounds to combat tumor cells. Observe the effect. Effect: Add FTS-IR783 (20μmol/L) to 3 cultured tumor cells, and observe the aggregation of fluorescent dyes in the tumor cells under a fluorescence microscope; 3 tumor cells (each 1×106) were transplanted naked. Two weeks later, mice carrying FTS-IR783 (10nmol/L each) were injected into the abdominal cavity, and the correlation between the near-infrared fluorescence signal at the tumor site and the tumor volume was determined by in vivo imaging.

  Result: Compared with FTS, FTS-IR783 can significantly inhibit the growth of MCF-7, U251 and PC3. Three types of tumor cells specifically recognize FTS-IR783 and exhibit near-infrared fluorescence aggregation. After subcutaneous injection of tumor model FTS-IR783, in vivo imaging showed that the correlation between the fluorescence intensity and bioluminescence intensity of the tumor site reached 0.987, 0.998 and 0.971, respectively.

  Conclusion: The combination of FTS and the near-infrared fluorescent dye IR-783 can specifically recognize tumor cells and can be used for in vivo imaging of tumor models. At the same time, the compound has tumor targeting properties that can significantly inhibit growth.